Cancer Incidence in BRCA1 mutation carriers.

By Deborah J. Thompson, D. Easton. Journal of the National Cancer Institute, 2002

1,225 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/9a5ad3011a5b9d68b42226a77e990afdabb091f6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Barbara L. Weber
2. Timothy R. Rebbeck
3. Nelson L. S. Tang
4. J. Peto

In Oncology

1. Barbara L. Weber
2. Timothy R. Rebbeck
3. A. Klein
4. J. Peto

In Public Health, Environmental and Occupational Health

1. Barbara L. Weber
2. J. Peto

Citations in the corpus

• Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review (2021, background): “31 Breast cancer Ovarian cancer Pancreatic cancer Fanconi anemia DNA repair Cell cycle control 45–87% [40]”
• Recent progress in pancreatic cancer (2013, background): “06) increased risk of pancreatic cancer in BRCA1 mutation carriers, other studies have not reported an increased prevalence of BRCA1 gene mutations in patients with pancreatic cancer.(24,32,33) The associations of germline BRCA2, PALB2 and possibly BRCA1 gene mutations with pancreatic cancer make it”
• Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. (2003, background): “Breast and ovarian cancer risk estimates are generally higher in studies that are based on multiple-case families (Ford et al. 1994, 1998; Easton et al. 1995) than in those that are based on unselected series (Thorlacius et al. 1998; Hopper et al. 1999; Warner et al. 1999; Anglian Breast Cancer…”
• Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. (2004, result): “These values are not substantially different than those of the penetrance reported in multiple studies of women with BRCA1 or BRCA2 mutations [10,11].”
• International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer (2012, background): “3).(30) No agreement was reached on the question of screening BRCA2 mutation carriers with no family history of PC (agree 51.”
• Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. (2002, methodology): “The accompanying Breast Cancer Linkage Consortium (BCLC) study ( 10 ) used 96 of these 147 families and included 2120 people from those pedigrees, with individuals from our clinic populations making up approximately 15% of the BCLC study.”